Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The New York Proton Center
Beijing Biotech
Parabilis Medicines, Inc.
Orano Med LLC
Filamon LTD
AstraZeneca
UMC Utrecht
Essen Biotech
Essen Biotech
Sapience Therapeutics
University of Nebraska
Adela, Inc
Dysplasia Diagnostics Limited
Mayo Clinic
Mayo Clinic
Dana-Farber Cancer Institute
Massive Bio, Inc.
Incyte Corporation
AVM Biotechnology Inc
Maastricht Radiation Oncology
Massachusetts General Hospital
Dana-Farber Cancer Institute
Washington University School of Medicine
Fudan University
Jonsson Comprehensive Cancer Center
University of California, San Francisco
Eli Lilly and Company
Columbia University
Tempus AI
Xijing Hospital
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
National Cancer Institute (NCI)
Universidade Federal de Pernambuco
Taproot Health
VitaMed Research LLC
Mayo Clinic
University of Sydney
Peking Union Medical College Hospital
Cedars-Sinai Medical Center
N.N. Petrov National Medical Research Center of Oncology
Hospices Civils de Lyon
M.D. Anderson Cancer Center
Nuvation Bio Inc.
Eastern Cooperative Oncology Group
Quadriga Biosciences, Inc.
Alliance for Clinical Trials in Oncology
Technische Universität Dresden
Institut Cancerologie de l'Ouest